| IV PEGylated rFVIII designed to prolong FVIII activity; has a longer terminal half-life and greater exposure than non-PEGylated FVIII and rFVIII products |
| Prophylaxis reduced spontaneous and joint ABRs in previously treated adults and adolescents |
| Effective in treating bleeding episodes and for perioperative management |
| Generally well tolerated with no confirmed cases of anti-FVIII inhibitor development |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.